Tu P, Li G Q, Zhu X J, Zheng J, Wong W Z
Department of Dermatology, First Hospital, Peking University, Beijing, China.
J Eur Acad Dermatol Venereol. 2001;15 Suppl 3:31-6. doi: 10.1046/j.0926-9959.2001.00010.x.
To compare the efficacy, safety and tolerability of adapalene gel 0.1% vs. tretinoingel 0.025% in a Chinese patient population.
Although acne vulgaris is a common problem among Asians and Asian-Americans, little has been published on the specific manifestations, sequelae, and treatment-responsiveness of this disorder in Asian skin types. Since Asian skin types tend to be more highly pigmented than those of white people of European descent, many Asians share the predisposition toward postinflammatory hyperpigmentation seen in Africans, African-Americans and other dark-skinned peoples. It is generally assumed that the efficacy and safety of topical retinoids is the same in Asians as in white people. Tretinoin has been available in China for decades; adapalene became available in 1998.
A total of 150 patients with grade II-III acne vulgaris seen at three dermatology clinics were randomized to 8 weeks of daily treatment with either adapalene gel 0.1% or tretinoin gel 0.025%. Counts of total lesions, inflammatory lesions and non-inflammatory lesions were made at baseline and again at treatment weeks 2, 4, 6 and 8. Global assessment ratings, based on percent lesion reduction from baseline were also made. Erythema, burning, pruritus, scaling and dryness were rated on a 0-3 severity scale.
A total of 139 patients completed the efficacy evaluation, and 144 patients completed the safety evaluation. Both adapalene and tretinoin produce dramatic reductions in total, inflammatory and non-inflammatory lesion counts, in the range of 69-74% on average. More than 70% of patients in both groups had complete clearance or marked improvement. In general, irritation was mild, but was both more common and more severe in the tretinoin group vs. the adapalene group. No systemic side effects were seen.
Adapalene offers comparable efficacy to tretinoin, but is less irritating. It represents a good alternative for the treatment of mild to moderate acne vulgaris in Chinese patients.
比较0.1%阿达帕林凝胶与0.025%维甲酸凝胶在中国患者群体中的疗效、安全性和耐受性。
虽然寻常痤疮在亚洲人和亚裔美国人中是一个常见问题,但关于这种疾病在亚洲皮肤类型中的具体表现、后遗症和治疗反应性的报道很少。由于亚洲皮肤类型往往比欧洲血统的白人色素沉着更严重,许多亚洲人与非洲人、非裔美国人和其他深色皮肤人群一样,易出现炎症后色素沉着。一般认为,外用维甲酸类药物在亚洲人和白人中的疗效和安全性相同。维甲酸在中国已上市数十年;阿达帕林于1998年上市。
在三家皮肤科诊所就诊的150例II - III级寻常痤疮患者被随机分为两组,分别接受为期8周的每日0.1%阿达帕林凝胶或0.025%维甲酸凝胶治疗。在基线时以及治疗第2、4、6和8周时,对总皮损、炎性皮损和非炎性皮损进行计数。还根据相对于基线的皮损减少百分比进行整体评估评分。红斑、灼痛、瘙痒、脱屑和干燥按0 - 3级严重程度评分。
共有139例患者完成疗效评估,144例患者完成安全性评估。阿达帕林和维甲酸均使总皮损、炎性皮损和非炎性皮损计数显著减少,平均减少幅度在69 - 74%之间。两组中超过70%的患者皮损完全清除或明显改善。总体而言,刺激症状较轻,但维甲酸组比阿达帕林组更常见且更严重。未观察到全身副作用。
阿达帕林与维甲酸疗效相当,但刺激性较小。它是治疗中国患者轻至中度寻常痤疮的良好替代药物。